CRISPR Therapeutics to Present at Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to present at the following investor conferences in June:

Jefferies 2019 Healthcare Conference Date: Tuesday, June 4, 2019Presentation: 11:30 a.m. ET Location: New York, NY

Goldman Sachs 40th Annual Global Healthcare Conference Date: Wednesday, June 12, 2019 Presentation: 8:40 a.m. PT Location: Rancho Palos Verdes, CA

A live webcast of the events will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following each presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR Investor Contact:Susan Kim[email protected]

CRISPR Media Contact:Jennifer PaganelliWCG on behalf of CRISPR347-658-8290[email protected]

You May Also Be Interested In

• Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
• Sui Price Prediction: Can SUI Hit $5 as Next Crypto To Explode AlphaPepe Builds Four Products Pre-Launch?
• Memecoin AI Agent Trading 2026: How MemeToro Could Redefine Automated Crypto Launches